A need for effective topical therapies for atopic dermatitis (AD) is essential without concerns about body surface area restriction or long-term treatment duration. This study assessed the efficacy and safety of tapinarof, an aryl hydrocarbon receptor modulating agent, in patients with AD.
Read more at the Journal of the American Academy of Dermatology.